证券之星消息，8月5日医疗美容板块较上一交易日上涨0.41%，锦波生物领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净点比 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 271.70万 | 17.26% | -314.88万 | -20.00% | 43.17万 | 2.74% | | 300896 爱美客 | -244.71万 | -0.61% | 2272.19万 | 5.64% | -2027.48万 | -5.04% | | 688363 华熙生物 | -618.47万 | -4.84% | 768.54万 | 6.01% | -150.07万 | -1.17% | 从资金流向上来看，当日医疗美容板块主力资金净流出591.48万元，游资资金净流入2725.85万元，散户 资金净流出2134.38万元。医疗美容板块个股资金流向见下表： ...

证券之星消息，8月4日医疗美容板块较上一交易日下跌0.9%，*ST美谷领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出5284.74万元，游资资金净流入2440.66万元，散户 资金净流入2844.08万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 183.25 | -0.69% | 2.05万 | 3.73 Z | | 832982 | 锦波生物 | 319.85 | -0.95% | 7186.67 | 2.30 Z | | 688363 | 华熙生物 | 51.35 | -1.15% | 2.85万 | 1.46 Z | | 000615 | *ST美谷 | 3.0 ...

Industry Overview - The medical beauty industry in China has developed rapidly despite its late start, with a comprehensive industry chain that includes upstream raw material suppliers and medical equipment providers, midstream public and private institutions, and downstream consumers [1][2]. Key Players - Major upstream raw material manufacturers include Huaxi Biological, Aimeike, Haohai Biological, Huadong Pharmaceutical, and Jiao Dian Biological, while medical equipment is primarily supplied by foreign leading manufacturers [2]. - Midstream medical institutions consist of well-known entities such as Huahan Plastic Surgery, Lido Plastic Surgery, and Ruile Medical, along with emerging platforms like Xinyang and Gem [2]. Regional Distribution - The coastal regions of China have a dense distribution of representative enterprises in the medical beauty industry, with significant concentrations in Beijing, Shanghai, and Guangzhou, which are home to top research institutions and production companies [5]. - These regions attract numerous renowned medical beauty hospitals and clinics, providing comprehensive and high-quality services to consumers [5]. Business Layout of Representative Companies - Companies like Aimeike and Huaxi Biological focus on domestic sales, while others like Langzi and Huahan have diversified regional strategies across various provinces [7]. - Some companies specialize in product development, while others emphasize service delivery, with notable examples including Aimeike and Haohai focusing on product R&D, and Aoyuan Meigu's strong hospital brand image [7]. Financial Performance - Aimeike reported a medical beauty business revenue of 3.023 billion yuan, with a business proportion of 99.90%, indicating a strong focus on medical devices [8]. - Huadong Pharmaceutical generated 2.041 billion yuan from its medical beauty segment, accounting for 4.87% of its total business [9]. Investment Trends and Future Plans - Companies are actively expanding their business layouts with a trend towards diversification and internationalization, such as Aimeike's acquisition of a Korean company and Haohai's collaboration with a U.S. firm for product innovation [10][11]. - Huadong Pharmaceutical is expanding its medical beauty business through acquisitions and partnerships, while Huaxi Biological is investing in new technologies and products [10][11].

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Views - The report highlights the strong performance of domestic brands in the skincare and cosmetics sectors on platforms like Douyin, with significant market share gains [5][25][28] - The report emphasizes the importance of emotional consumption trends driving growth in various retail segments, particularly in jewelry, cosmetics, and offline retail [30][31] Summary by Sections Retail Market Overview - The retail industry index decreased by 2.22% during the week of July 28 to August 1, 2025, underperforming the Shanghai Composite Index by 1.28 percentage points [7][14] - The professional chain segment showed the largest increase among retail sub-sectors, while the jewelry sector led the year-to-date performance with a 25.38% increase [17][20] Key Industry Dynamics - In July, Douyin's skincare brand Han Shu ranked first, with domestic brands occupying 15 out of the top 20 spots in the skincare category [25][28] - The cosmetics sector also saw domestic brands excel, with 19 out of the top 20 positions in the makeup category, driven by cushion products and other high-demand items [28][29] Investment Recommendations - Investment focus areas include: - **Jewelry**: Recommend brands with differentiated product offerings like Laopuhuang and Chaohongji [30][33] - **Offline Retail**: Highlight companies like Yonghui Supermarket and Aiyingshi that are adapting to consumer trends [30][31] - **Cosmetics**: Emphasize domestic brands with strong market positions such as Maogeping and Pola [31][32] - **Medical Aesthetics**: Focus on companies with unique product lines like Aimeike and Kedi-B [31][32] Company-Specific Insights - **Laopuhuang**: Achieved revenue of 8.506 billion yuan (+167.5%) and a net profit of 1.473 billion yuan (+253.9%) in FY2024, with strong growth expected in H1 2025 [32] - **Yonghui Supermarket**: Reported a revenue of 17.479 billion yuan (-19.3%) and a net profit of 148 million yuan (-80.0%) in Q1 2025, with ongoing transformation efforts [32] - **Maogeping**: Recorded a revenue of 3.885 billion yuan (+34.6%) and a net profit of 881 million yuan (+33.0%) in FY2024, indicating strong brand momentum [32]

Investment Rating - The report suggests a positive outlook for domestic brands and a recovery for international beauty brands in the Chinese market, indicating potential investment opportunities in the cosmetics and medical beauty sectors [2][3]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 3.3% from July 25 to August 1, 2025, while the Shenwan Cosmetics Index fell by 2.6% [3][4]. - Domestic brands showed strong growth during the off-season, with notable increases such as Han Shu up 58%, Proya up 23%, Marubi up 72%, and Kefu Mei up 28%, indicating resilience in the market [7][17]. - International beauty brands, represented by L'Oréal, are recovering in the Chinese market, with a 3% growth in Q2 2025, supported by promotional events like the 618 shopping festival [7][24]. - The report highlights the success of Lin Qingxuan, a high-end domestic skincare brand, which saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, showcasing the potential of domestic brands [13][14]. Summary by Sections Industry Performance - The beauty and medical aesthetics sector has shown weaker performance compared to the overall market, with specific indices declining [3][4]. - The report notes that the cosmetics market is transitioning from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of cosmetics sales in 2024, up from 22% in 2016 [9][30]. Key Company Highlights - L'Oréal's sales in China for H1 2025 reached approximately 186.19 billion yuan, with a 3% year-on-year increase, indicating a recovery in the Chinese market [24]. - Procter & Gamble reported a record net sales of approximately 604.95 billion yuan for the 2025 fiscal year, with the beauty segment achieving a net sales of approximately 107.66 billion yuan, reflecting a 2% growth [25]. - Lin Qingxuan's product matrix includes 188 SKUs, with a focus on high-quality natural ingredients, and it has established a strong supply chain and distribution network [14][16]. Market Trends - The report emphasizes the growing market for high-end skincare products, with the market size expected to increase from 749 billion yuan in 2019 to 1,144 billion yuan by 2024, indicating a compound annual growth rate (CAGR) of 13.8% [14][15]. - The domestic brands are gaining market share, with the top ten brands in the skincare market now evenly split between domestic and international brands, reflecting a shift in consumer preferences [30][31].

（原标题：美容护理行业本周跌3.30%，主力资金净流出8.22亿元） 美容护理行业资金流向排名 | 代码 | 简称 | 一周涨跌幅（%） | 一周换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300896 | 爱美客 | -3.67 | 7.50 | -16152.43 | | 300888 | 稳健医疗 | -5.58 | 23.81 | -9903.50 | | 002094 | 青岛金王 | -3.69 | 34.44 | -8144.37 | | --- | --- | --- | --- | --- | | 603605 | 珀莱雅 | -2.38 | 6.47 | -7231.63 | | 300957 | 贝泰妮 | -3.08 | 4.64 | -6270.02 | | 002511 | 中顺洁柔 | -3.18 | 10.53 | -4998.09 | | 688363 | 华熙生物 | -3.49 | 4.95 | -4676.63 | | 603630 | 拉芳家化 | -6.52 | 16.54 | -4086.99 | ...

Group 1 - The company, Aimeike, stated on August 1 that as of July 31, 2025, the number of shareholders will be 55,143 [2]

证券之星消息，8月1日医疗美容板块较上一交易日上涨0.06%，*ST美谷领涨。当日上证指数报收于 3559.95，下跌0.37%。深证成指报收于10991.32，下跌0.17%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.12 | 2.30% | 11.73万 | 3619.67万 | | 688363 | 华熙生物 | 56'15 | 0.25% | 3.01万 | 1.57 Z | | 300896 | 爱美客 | 184.53 | -0.20% | 2.32万 | 4.31亿 | | 832982 | 锦波生物 | 322.91 | -3.46% | 1.04万 | 3.39亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1180.44万元，游资资金净流入977.47万元，散户 资金净流入202.97万元。医疗美容板块个股资金流向见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元 ...

Core Insights - The total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The highest annual salary for a CFO in the beauty and skincare industry was 2.933 million yuan, paid to Wang Li of Proya [2][3] - There are nearly 12 listed companies in the beauty and skincare sector where CFO salaries exceed 1 million yuan [2] Salary Overview - The average annual salary for CFOs in the beauty and skincare industry is 770,000 yuan [1] - The highest salaries among CFOs in this sector include: - Proya: 2.933 million yuan - Betaini: 2.82 million yuan - Aimeike: 2.335 million yuan - Baiya: 2.048 million yuan - Sturdy Medical: 2.015 million yuan [2][3] Company Performance - Qing Song Co.'s CFO, Wang Yucai, has seen the company's revenue decline for four consecutive years, with net profit once falling into the red [1][4] - Sturdy Medical's accounts receivable growth rate outpaced revenue growth, leading to a rising accounts receivable to revenue ratio and declining gross profit margin [3] - Aimeike experienced a significant slowdown in revenue and net profit growth, with multiple profitability indicators declining [3][4] - Betaini reported increased revenue but decreased profitability, with several operational capability indicators also declining [4] Age Demographics of CFOs - The youngest CFOs in the industry are Wang Yucai from Qing Song Co. and Zou Fei from Shui Yang Co., both aged 35 [4] - The oldest CFO is Dong Ye from Zhongshun Jierou, aged 61 [4]

Core Insights - The total salary scale for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - The highest annual salary for a CFO in the beauty and skincare industry was 2.93 million yuan, paid to Wang Li of Proya [2][3] - The beauty and skincare industry CFOs' average salary was reported at 770,000 yuan, with nearly 12 companies having CFO salaries exceeding 1 million yuan [2] Salary Breakdown - The top five CFO salaries in the beauty and skincare sector are as follows: - Proya: 2.93 million yuan - Beitaini: 2.82 million yuan - Aimeike: 2.34 million yuan - Baiya: 2.04 million yuan - Sturdy Medical: 2.02 million yuan [2][3] - Companies with CFO salaries exceeding 2 million yuan include Sturdy Medical, Baiya, Aimeike, Beitaini, and Proya [2] Industry Performance - Aimeike experienced a significant slowdown in revenue and net profit growth, with declines in multiple profitability indicators, including sales gross margin and return on equity [1][3] - Beitaini also reported a decline in profitability metrics, with decreasing sales gross margin and return on equity, alongside a drop in operational efficiency indicators [4] - Sturdy Medical's accounts receivable growth outpaced revenue growth, leading to an increase in the accounts receivable to revenue ratio and a decline in sales gross margin [3]